BBIO vs. OGN, APLS, MDGL, IONS, NUVL, ALPN, PRGO, ALKS, INSM, and BPMC
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
Organon & Co. has a net margin of 16.50% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Organon & Co.'s return on equity.
BridgeBio Pharma currently has a consensus price target of $47.82, indicating a potential upside of 67.78%. Organon & Co. has a consensus price target of $22.60, indicating a potential upside of 7.93%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Organon & Co..
BridgeBio Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
In the previous week, Organon & Co. had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for Organon & Co. and 5 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.76 beat Organon & Co.'s score of 0.63 indicating that BridgeBio Pharma is being referred to more favorably in the media.
99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 28.5% of BridgeBio Pharma shares are held by insiders. Comparatively, 1.2% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
BridgeBio Pharma received 122 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.32% of users gave BridgeBio Pharma an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Summary
BridgeBio Pharma beats Organon & Co. on 11 of the 18 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
